Type 2 diabetes

News

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.

News

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments.